OrbiMed’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

OrbiMed’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-107,300	Closed	-$668K	–	151
2016 Q3	$668K	Hold	107,300	–	–	0.01%	134
2016 Q2	$481K	Hold	107,300	–	–	0.01%	134
2016 Q1	$1.13M	Hold	107,300	–	–	0.01%	135
2015 Q4	$3.17M	Hold	107,300	–	–	0.03%	115
2015 Q3	$3.39M	Hold	107,300	–	–	0.03%	118
2015 Q2	$6.35M	Hold	107,300	–	–	0.05%	117
2015 Q1	$11.5M	Hold	107,300	–	–	0.1%	99
2014 Q4	$10.1M	Hold	107,300	–	–	0.1%	93
2014 Q3	$8.24M	Sell	107,300 -5,760	-5%	-$454K	0.09%	99
2014 Q2	$10.2M	Sell	113,060 -106,790	-49%	-$6.54M	0.12%	85
2014 Q1	$11.8M	Sell	219,850 -12,230	-5%	-$404K	0.14%	83
2013 Q4	$5.85M	Hold	232,080	–	–	0.09%	94
2013 Q3	$6.31M	Hold	232,080	–	–	0.11%	95
2013 Q2	$8.38M	Buy	+232,080	New	+$8.7M	0.18%	84

Other funds holding PTX

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

OrbiMed's PTX Position: Q4 2016 in Review

OrbiMed sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q4 2016, closing a stake of 107,300 shares — an estimated $668K sold.

OrbiMed first reported a position in PTX in Q2 2013 and held it in 14 quarters. The position peaked at $11.8M in Q1 2014. 34 funds tracked by Wall St. Rank hold PTX as of Q4 2016.

OrbiMed reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q4 2016 after selling out during the quarter.
OrbiMed sold 107,300 Pernix Therapeutics Holdings, Inc. shares in Q4 2016, an estimated $668K.
OrbiMed first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2013 and held it in 14 quarters.
OrbiMed's Pernix Therapeutics Holdings, Inc. position peaked at $11.8M in Q1 2014.
34 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q4 2016.

Based on OrbiMed's 13F filing for Q4 2016, filed 14 Feb 2017.